Stockscreener 앱 받기
28.50
2.30%
-0.67
시장 영업 전:
28.50
전일 마감가:
$29.17
열려 있는:
$29.26
하루 거래량:
1.48M
Relative Volume:
0.64
시가총액:
$4.71B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
14.62
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
-3.46%
1개월 성능:
-9.25%
6개월 성능:
-7.41%
1년 성능:
-6.56%
1일 변동 폭
$28.42
$29.35
1주일 범위
$27.80
$29.80
52주 변동 폭
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.50 | 4.82B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-11 | 개시 | Truist | Buy |
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Frazier Life Sciences Management L.P. Boosts Stock Position in Alkermes plc $ALKS - MarketBeat
EcoR1 Capital LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat
Retail Surge: Why global investors buy Alkermes plc 8AK stockCEO Change & Expert Curated Trade Ideas - moha.gov.vn
History Review: Will Alkermes plc 8AK stock test record highs in 2025Watch List & High Conviction Investment Ideas - moha.gov.vn
BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com South Africa
BlackRock increases stake in Alkermes to 17% - Investing.com
Stempoint Capital LP Acquires 158,772 Shares of Alkermes plc $ALKS - MarketBeat
First Trust Advisors LP Has $39.98 Million Stock Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes, Avadel Pharmaceuticals merger gets HSR clearance in US - MLex
Avadel Pharmaceuticals Acquisition by Alkermes Advances - TradingView — Track All Markets
Are Investors Undervaluing Alkermes (ALKS) Right Now? - sharewise.com
(ALKS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Schroder Investment Management Group Invests $1.39 Million in Alkermes plc $ALKS - MarketBeat
Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 3,748 Shares of Stock - MarketBeat
Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - MSN
Norges Bank Invests $53.33 Million in Alkermes plc $ALKS - MarketBeat
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
Avadel Pharmaceuticals plc and Alkermes plc Announce Proposed Transaction for Acquisition - Quiver Quantitative
Announcement relating to despatch of Rule 15 proposal - The Manila Times
Avadel (NASDAQ: AVDL) sends Rule 15 proposal to equity holders in Alkermes deal - Stock Titan
Capital Fund Management S.A. Makes New $1.14 Million Investment in Alkermes plc $ALKS - MarketBeat
Will Alkermes plc (8AK) stock sustain bullish trend into 2025Fed Meeting & Smart Money Movement Tracker - Newser
ALKS: Elixirxton demonstrates strong efficacy, safety, and dosing flexibility for narcolepsy and hypersomnolence - TradingView
Avadel Pharmaceuticals Announces Mailing of Definitive Proxy Statement Regarding Proposed Acquisition by Alkermes - Quiver Quantitative
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting - Benzinga
Avadel (Nasdaq: AVDL) mails proxy, sets Jan. 12 scheme and EGM on Alkermes deal - Stock Titan
VP Hopkinson Files To Sell 3,748 Of Alkermes PLC [ALKS] - TradingView
Mackenzie Financial Corp Acquires 53,323 Shares of Alkermes plc $ALKS - MarketBeat
Evercore Healthcare Conference - marketscreener.com
How Alkermes plc (8AK) stock valuation compares with sectorQuarterly Profit Report & Daily Profit Focused Screening - Newser
Is Alkermes plc (8AK) stock a safe buy pre earningsMarket Growth Summary & Real-Time Sentiment Analysis - Newser
Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 4,000 Shares of Stock - MarketBeat
Regeneron, Tessera to advance gene editing therapy for AATD: Deals Report - BioCentury
How supply chain issues affect Alkermes plc stockPortfolio Performance Report & Real-Time Stock Movement Alerts - Newser
Should Alkermes (ALKS) Investors Reassess Prospects After Raised 2025 Guidance and Strong Q3 Results? - Yahoo Finance
Is Alkermes plc (8AK) stock among top earnings playsQuarterly Trade Review & Real-Time Volume Surge Alerts - Newser
Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes plc. Officer Sells 4,000 Shares - TradingView
VP Hopkinson Sells 4,000 ($117.2K) Of Alkermes PLC [ALKS] - TradingView
Avadel Pharmaceuticals plc Announces Scheme Meeting for Alkermes Acquisition Proposal - Quiver Quantitative
Avadel Pharmaceuticals (Nasdaq: AVDL) to hold Scheme and EGM on Alkermes takeover Jan. 12 - Stock Titan
Rhumbline Advisers Purchases 17,660 Shares of Alkermes plc $ALKS - MarketBeat
Legal & General Group Plc Sells 17,227 Shares of Alkermes plc $ALKS - MarketBeat
Loomis Sayles & Co. L P Sells 330,389 Shares of Alkermes plc $ALKS - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes plc $ALKS Shares Sold by Ensign Peak Advisors Inc - MarketBeat
JPMorgan discloses securities dealings in Avadel Pharmaceuticals - Investing.com
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study - Sahm
Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? - sharewise.com
Avadel (AVDL) Drops 6.7% on Lack of Leads - Finviz
Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt - Citeline News & Insights
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alkermes Plc 주식 (ALKS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Dec 03 '25 |
Sale |
30.00 |
3,748 |
112,447 |
65,740 |
1.48%
0.09%
자본화:
|
볼륨(24시간):